Navigation Links
Pharmaxis Previews New Bronchial Challenge Test at the Annual Meeting of the American College of Allergy, Asthma and Immunology
Date:11/10/2010

s complete in approximately 20 minutes, compared to an average of 44 minutes for a methacholine test.(1)  A methacholine test requires a nebulizer to administer, a 20% reduction in FEV1 and a designated testing room with ventilation.(2)  Tests that use exercise to assess bronchial hyperresponsiveness require special equipment and conditions, and may not be appropriate for patients with physical limitations.

How ARIDOL Works

The ARIDOL test requires patients to inhale increasing doses of dry powder mannitol from a simple, hand-held device, which causes airways to narrow and contract when airway inflammation is present. The doses are contained in capsules that are administered at one-minute intervals until a positive response is achieved or until all the capsules have been inhaled, indicating a negative test result.   A positive response is indicated when there is a 15% reduction in (FEV1) from baseline or a 10% incremental reduction in (FEV1) between successive doses.  The lower the dose required to cause bronchoconstriction, the more severe the bronchial hyperresponsiveness.  

Safety/Efficacy Profile

The safety and efficacy of ARIDOL as a bronchial challenge test were demonstrated in two global Phase III clinical trials, which assessed the effectiveness of the ARIDOL bronchial challenge test in patients with symptoms suggestive of asthma and in clinically diagnosed asthmatic patients six years of age and older.  ARIDOL demonstrated consistent effectiveness across both study populations.  Approved for use in 19 countries, ARIDOL has been used by more than 44,000 patients, and is marketed in Australia, major European countries and Korea.  

ARIDOL is included in official international guidelines for the clinical assessment of asthma. Organizations and guidelines endorsing ARIDOL include: the International Olympic Committee Medical Commission's Independent Panel on Asthma, the U.S.
'/>"/>

SOURCE Pharmaxis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmaxis Long-Term Safety Study of Bronchitol Completes
2. Pharmaxis Establishes Named Patient Program for Bronchitol
3. Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial
4. ASX/NASDAQ Media Release: Pharmaxis Files First Marketing Application for Bronchitol in Australia
5. Pharmaxis Announces New Drug Application Submission for Aridol(TM)
6. Pharmaxis Announces Milestone in Phase III Trial for Cystic Fibrosis
7. Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial
8. FDA Approves Pharmaxis ARIDOL™ (Mannitol Inhalation Powder) Bronchial Challenge Test Kit for the Assessment of Bronchial Hyperresponsiveness
9. Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results
10. Emphasys Medical Granted Expedited Review From FDA for Zephyr(R) Endobronchial Valve
11. Pivotal Data Show Bronchial Thermoplasty Can Improve Quality of Life and Reduce Asthma Attacks and Emergency Room Visits for Adults with Severe Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... Oct. 20, 2014  Luoxis Diagnostics, Inc., a ... today announced that its academic collaborators will present ... potential for its novel RedoxSYS Diagnostic System, a ... the body in response to injury or illness.  ... as a clinical marker will be presented by ...
(Date:10/20/2014)...   BioNano Genomics announced today achievement of a ... human data at 30X depth, sufficient for a genome map, ... was established and demonstrated for the IrysChip TM V2, ... and will be rolled out to BioNano,s collaborators and ... this advancement at the American Society for Human Genetics ...
(Date:10/20/2014)... SAN DIEGO , Oct. 20, 2014 /PRNewswire/ ... the industry leader in bioactive lipid-targeted therapeutics, received official ... company has been granted another key patent supporting ... This newly issued patent, European patent No. 2087002, ... drug substance in Lpath,s two lead compounds, iSONEP ...
Breaking Medicine Technology:Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5BioNano Genomics Announces One Human : One Chip : One Day 2BioNano Genomics Announces One Human : One Chip : One Day 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4
... Nov. 15 GeoVax Labs, Inc. (OTC,Bulletin Board: GOVX), ... results and provided an,operational update for the quarter ended ... Ended September 30, 2007 The Company recorded a ... 30, 2007, compared to $283,434 for the same period ...
... Collaborative Meeting Includes Leading Scientists Investigating ... Pregnancy and Breast Cancer Prevention, HOUSTON, Nov. ... breast cancer by studying the natural,impact of pregnancy on breast ... November 12, 2007 to share interim findings. All are,part of ...
Cached Medicine Technology:GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update 2GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update 3GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update 4GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update 5GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update 6GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update 7GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update 8GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update 9GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update 10Grantees of the Avon Foundation Breast Cancer Prevention Research Initiative Gather in Houston to Report Interim Findings 2Grantees of the Avon Foundation Breast Cancer Prevention Research Initiative Gather in Houston to Report Interim Findings 3
(Date:10/20/2014)... Principle Business Enterprises, a family owned company for ... products. The company has recently made efforts to ... Premium Protection absorbent products. The company has redesigned ... a new look, and is currently working on innovative ... , The new website, developed with Thread Marketing Group ...
(Date:10/20/2014)... Succeed is proud to announce that they ... in the Every Body Walk! campaign by Kaiser ... that encourages workers to be more active outside of the ... concluded at the end of September, was a friendly competition ... areas. Participating companies gave their staff pedometers and each ...
(Date:10/20/2014)... Unveiled at the Sept. 18 board meeting, The Center ... hospital ROI on membership dues at 12.5. In other words, ... in value to member hospitals. The calculation used to determine ... , “This is the first time we’ve actually been ... methodology is really sound,” said Bill Ryan , president ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Do you ... interventions? Here comes a wonderful app Metassessor for teachers, ... development company helped its client “Intervention Development LLC” ... The app is designed for iOS 4.3 or later ... This app is optimized for iPhone 5. It is ...
(Date:10/19/2014)... 19, 2014 Dr. Babatunde Osotimehin, Executive ... news of a ceasefire agreement that is expected to ... girls who were kidnapped from the north-eastern Nigerian town ... captivity long enough, and it is high time they ... Dr. Osotimehin. , "We owe it to these girls ...
Breaking Medicine News(10 mins):Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3
... Metropolitan Health Plan (MHP(R)),the HMO of Hennepin County, announced ... Financial Officer and David R. Johnson,Executive Director., David ... for over 35,years. During his tenure at MHP, the ... Assistance, to a plan that offers 10 government,sponsored plans ...
... A key protein change can lessen the cholesterol-lowering drugs, ... genetic quirk in the production of one protein helps ... benefit of statin drugs, researchers report. , Statins include ... , The protein, abbreviated as HMGCR, plays a critical ...
... Many women experience menopausal changes in their body ... they don,t notice can be more dangerous. In a ... discovered significant changes in the brain,s vascular system when ... currently used estrogen-based hormone therapies may complicate this process ...
... PITTSBURGH, June 16 Mylan Inc. (NYSE: ... Inc., has,received final approval from the U.S. Food ... Application (ANDA) for Venlafaxine,Hydrochloride (HCl) Tablets 25 mg ... (base) and 100 mg (base)., Venlafaxine HCl ...
... 16 /PRNewswire-FirstCall/ - MaxLife Fund Corp.,(OTC:MXFD), is pleased to ... shareholders of its outstanding preferred shares. The,dividend declared is ... quarterly. Each preferred share was sold at $25 per ... Fund Corp., The dividend is payable August 31, ...
... studies evaluating dietary changes and complementary medicine for the ... at Rush University Medical Center. Funded by the ... the impact of mind/body medicine on patients suffering from ... diet impacts patients with Crohn,s Disease. , ...
Cached Medicine News:Health News:Metropolitan Health Plan Announces Senior Management Appointments 2Health News:Research Shows Why Statins Don't Work for Everyone 2Health News:Complex changes in the brain's vascular system occur after menopause 2Health News:MaxLife Fund Corp. declares dividends to shareholders of Preferred Shares. 2Health News:Study underway to find an alternative cure for Crohn's disease and ulcerative colitis 2
... tests confirmed Sterillium Rub's extremely effective and ... (Time Kill study and Tentative Final Monograph ... one European test - with the result ... efficacy specifications. Sterillium Rub with its high ...
Chlorhexidine Gluconate, exceptionally persistent and broad spectrum antimicrobial properties have led to its recognition as the most effective agent available for surgical scrubbing, hand washing, p...
Amino+Derm moisturizers and soaps are specifically engineered to aid in the prevention of skin irritations and to help maintain healthy, intact skin....
... plus Neu Thera is ... alcohol hand sanitizer that ... of the Neu-Thera technology. ... clinically proven to be ...
Medicine Products: